ER Status Prediction on TCGA-BRCA internal cohort
99.4AUCHERO
Evaluation results
| Method | Links | |||
|---|---|---|---|---|
| HERObackbone=LoRA-tuned Qwen2.5-VL-7B2026.06 | 99.4 | — | — | |
| SurvPathreimplementation=true2026.06 | 99.1 | — | — | |
| MOTCatreimplementation=true2026.06 | 98.2 | — | — | |
| MCATreimplementation=true2026.06 | 97.5 | — | — | |
| SNNTransreimplementation=true2026.06 | 96.8 | — | — | |
| MDAgentreimplementation=true2026.06 | 96.5 | — | — | |
| VLM + TransMIL Top-64backbone=LoRA-tuned Qwen2.5-VL-7B, retrieval=TransMIL-selected Top-64 evidence2026.06 | 96.2 | — | — | |
| MKD (Ours)Modality=Multi-modal2025.08 | 95.81 | 90.24 | 93.67 | |
| SNNreimplementation=true2026.06 | 95.2 | — | — | |
| MCATModality=Multi-modal2025.08 | 94.64 | 90.41 | 93.68 | |
| GPT-4oreimplementation=true2026.06 | 94.5 | — | — | |
| CMTAModality=Multi-modal2025.08 | 93.91 | 89.44 | 93.15 | |
| MKD (Ours)Modality=Pathology2025.08 | 93.31 | 88.47 | 92.58 | |
| PorpoiseModality=Multi-modal2025.08 | 92.64 | 89.86 | 93.28 | |
| TransMIL2026.06 | 90.1 | — | — | |
| GEEModality=Pathology2025.08 | 90.01 | 84.3 | 89.37 | |
| DTFDModality=Pathology2025.08 | 89.89 | 86.66 | 91.37 | |
| DAMLNModality=Pathology2025.08 | 89.58 | 85.97 | 91.39 | |
| RRTModality=Pathology2025.08 | 89.35 | 83.33 | 88.28 | |
| TDCModality=Pathology2025.08 | 89.35 | 83.33 | 88.28 | |
| CLAMModality=Pathology2025.08 | 89.2 | 85.69 | 90.68 | |
| ABMILModality=Pathology2025.08 | 88.91 | 84.85 | 89.84 | |
| ABMIL2026.06 | 88.5 | — | — | |
| WIKGModality=Pathology2025.08 | 88.05 | 84.44 | 90.1 | |
| TransMILModality=Pathology2025.08 | 87.77 | 86.94 | 91.82 | |
| VLM + Rand. Top-64backbone=LoRA-tuned Qwen2.5-VL-7B, retrieval=Random Top-64 evidence2026.06 | 84.5 | — | — |